Exosystems to conduct trial run of new ICT rehabilitation solution in Vietnam

Food and Healthcare Press Releases Thursday October 11, 2018 08:25
SEOUL, South Korea--11 Oct--PRNewswire/InfoQuest
The healthcare robotics company Exosystems will soon be conducting a trial run of its ICT muscular rehabilitation solution "ExoRehab" at hospitals in Vietnam.

Exosystems, a member company of the K-ICT Born2Global Centre, has signed a partnership contract with Medipeace Vietnam, which is already involved in local rehabilitative care projects, and plans to introduce ExoRehab in Vietnamese hospitals by December 2018. Medipeace is an NGO that conducts medical support projects around the world.

Developed independently by Exosystems, ExoRehab is a next-generation muscular rehabilitation solution that combines medical treatment with information and communications technology. Used in conjunction with neuromuscular electrical stimulation (NMES), the treatment method currently in use, it has patients play rehabilitative games developed by medical professionals and provides a systematic rehabilitative care program. ExoRehab effectively accelerates patients' rehabilitation rates and assists medical personnel in the provision of effective patient care and management.

Through its partnership with Medipeace Vietnam, Exosystems will be entering both the Korean and international rehabilitation markets. The conformance test for ExoRehab was completed at Wonju Severance Christian Hospital in November 2017, and clinical testing with Seoul National University Bundang Hospital is currently underway. The product is scheduled to be released in the North American market in the second half of 2019.

Exosystems founder and CEO Hooman Lee said, "Exosystems completed the development and certification procedures for our ExoRehab device within just a year and a half after the company's founding in January 2017, and is working quickly to supply the product to our clients. We hope that the trial run of ExoRehab in Vietnam will promote the provision of advanced technology in the field of rehabilitative care, which is a major aspect of the problem of population aging that many countries around the world are now facing."

Exosystems was founded by researchers specialized in intelligent robotic systems who were formerly affiliated with the Electronics and Telecommunications Research Institute. In May 2017, the company received an investment of KRW 300 million from Kakao Ventures, a renowned Korean venture capital firm.

For more detailed information on Exosystems, visit https://www.exosystems.io/.
Media Contact
Hooman Lee
CEO of Exosystems
Jina Lee
PR Manager of Born2Global
Photo - https://photos.prnasia.com/prnh/20181005/2258781-1-a
Photo - https://photos.prnasia.com/prnh/20181008/2258781-1-b

Latest Press Release

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

5 Ways to Set Healthy Grocery Shopping Habits in 2019

By Susan Bowerman, M.S., RD, CSSD, CSOWM, FAN, Senior Director, Worldwide Nutrition Education and Training Make your daily staples as healthy as you can. Small changes in the foods you eat every day can add up to big rewards. The holidays are over, and...

Texas Cardiac Arrhythmia Institute at St. David#s Medical Center first in U.S. to treat patient in study to evaluate balloon ablation catheter for treating Atrial Fibrillation

The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently performed the first procedure in the U.S. using the new HELIOSTAR Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter as part of the STELLAR study. The study...

FDA Accepts sBLA and Grants Priority Review for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO(R) (avelumab) in combination with INLYTA(R) (axitinib)*...

BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"),...

Related Topics